Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 8/20 | 0.43 |
| ▸ | LCK | P06239 | 10/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.41 |
| ▸ | IL1B | P01584 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12098327 | 1.00 | MME (0.44) | MMEACECASP1LCKCASP3 | |
| SCHEMBL1410178 | 0.90 | LCK (0.45) | MMEACECASP1LCKCASP3 | |
| SCHEMBL1410179 | 0.90 | LCK (0.45) | MMEACECASP1LCKCASP3 | |
| SCHEMBL12098389 | 0.85 | ACE (0.58) | MMEACECASP1LCKIL1B | |
| SCHEMBL1409780 | 0.84 | CASP1 (0.64) | MMEACECASP1LCKCASP3 | |
| SCHEMBL3069962 | 0.84 | CASP1 (0.64) | MMEACECASP1LCKCASP3 | |
| SCHEMBL1409073 | 0.84 | ACE (0.39) | MMEACECASP1LCKCASP3 | |
| SCHEMBL1409076 | 0.84 | ACE (0.39) | MMEACECASP1LCKCASP3 | |
| SCHEMBL2219237 | 0.84 | CASP1 (0.59) | MMEACECASP1LCKCASP3 | |
| SCHEMBL1409094 | 0.84 | CASP1 (0.59) | MMEACECASP1LCKCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791161-B1 | INHIBITORS OF HCV NS5A | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-9180193-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9133170-B2 | Inhibitors of HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150166514-A1 | INHIBITORS OF HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20140255344-A1 | Antiviral Compounds | Hiffmann-La Roche Inc. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20120328565-A1 | ANTIVIRAL COMPOUNDS | BRINKMAN JOHN A (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | ALAM MUZAFFAR (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328565-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, HAVCR2, MAVS | MME 1409/4885ACE 104/4885CASP1 1834/4885 |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | MME 503/4885ACE 79/4885CASP1 2582/4885 |
| US-20140255344-A1 | Antiviral Compounds | EIF2AK2, HAVCR2, MAVS | MME 640/4885ACE 80/4885CASP1 2146/4885 |
| US-20150166514-A1 | INHIBITORS OF HCV NS5A | HAVCR2, EIF2AK2, MAVS | MME 729/4885ACE 1102/4885CASP1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.